BSX Plunges 60%: DeepValue Report Flags EP and Leverage Risks, but Contrarians See Opportunity

What happened

Boston Scientific shares have collapsed nearly 60% from their September 2025 high to around $45, prompting some investors to label it a "falling knife" worth catching. The DeepValue Master Report maintains a WAIT rating, citing that Q1 2026 already revealed worse-than-expected electrophysiology share loss and Watchman volume deceleration, while the company pursues a debt-funded $14.5B Penumbra acquisition alongside a $2B ASR. Management slashed 2026 organic growth guidance to 6.5-8.0%, and the bear-case scenario values the stock at $45 exactly—the current price—reflecting risk of further erosion in EP market position and financial flexibility. The author of the Seeking Alpha article bought shares at an average $45.52, arguing the reset is priced in, but the DeepValue analysis warns that without proof of stabilization in Q2–Q3 2026, the downside remains open. Ultimately, the stock's trajectory hinges on whether the guidance reset proves conservative or is the first of multiple cuts, against a backdrop of rising competitive pressure and a stretched balance sheet.

Implication

Long-term investors should require visible stabilization in EP share and Watchman volumes, plus clarity on Penumbra financing terms, before building a position. The report's attractive entry is $52, not $45, implying that even at the bear case, there is no margin of safety without operational proof.

Thesis delta

The DeepValue report rated BSX a WAIT at $57, arguing that downside to $45 was possible if EP and Watchman trends worsened. That bear case has now materialized, but the catalyst for re-entry—stabilization of competitive dynamics and leverage—remains absent. The thesis shifts from 'wait for stabilization' to 'monitor for the first signs of stabilization before the stock can re-rate above the bear case.'